Ticker Details
Vericel Corporation Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company. The company operates in one reportable segment: the research, manufacture, and distribution of patient-specific, used in the treatment of specific diseases.
IPO Date:	November 25, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.47B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.63 | 2.80%
Avg Daily Range (30 D):	$0.85 | 2.13%
Avg Daily Range (90 D):	$0.80 | 2.24%

Institutional Daily Volume
Avg Daily Volume:	.47M
Avg Daily Volume (30 D):	.47M
Avg Daily Volume (90 D):	.5M

Trade Size
Avg Trade Size (Sh.):	95
Avg Trade Size (Sh.) (30 D):	50
Avg Trade Size (Sh.) (90 D):	54

Institutional Trades
Total Institutional Trades:	3,234
Avg Institutional Trade:	$2.54M
Avg Institutional Trade (30 D):	$4.26M
Avg Institutional Trade (90 D):	$3.19M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.06M
Avg Closing Trade (30 D):	$6.36M
Avg Closing Trade (90 D):	$4.53M
Avg Closing Volume:	91.62K

News

May 5, 2026 @ 5:00 PM Global Stem Cell Therapy Market Set to Flourish at... Source: Delveinsight

Jan 13, 2026 @ 2:00 PM Vericel Announces Preliminary 2025 Financial Resul... Source: Na

Nov 6, 2025 @ 5:02 PM Brown Capital Discloses $31 Million Sale of Verice... Source: Jonathan Ponciano

Aug 14, 2025 @ 6:22 PM MediWound Revenue Jumps 43% in Q2 Source: Na

Aug 5, 2025 @ 7:14 PM Vericel Q2 Revenue Jumps 20% Source: Jesterai

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$.43	$-.12	$.46
Diluted EPS	$.42	$-.12	$.45
Revenue	$292.09M	$68.43M	$92.92M
Gross Profit	$218.59M	$49.27M	$73.13M
Net Income / Loss	$21.46M	$-6.3M	$23.24M
Operating Income / Loss	$15.77M	$-8.06M	$22.42M
Cost of Revenue	$73.49M	$19.16M	$19.79M
Net Cash Flow	$29.59M	$9.2M	$-.31M
PE Ratio

Splits
Oct 16, 2013	1:20
Feb 18, 2010	1:8